Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Am J Gastroenterol. 2021 Mar 1;116(3):522–529. doi: 10.14309/ajg.0000000000001045

Table 4.

Prediagnostic sex hormone concentrations and risk of gastrointestinal cancers in women in the UK Biobank

Esophageal adenocarcinoma Esophageal squamous cell carcinoma Gastric cancer Colorectal cancer
Person-years Cases Adjusted HR (95% CI) Cases Adjusted HR (95% CI) Cases Adjusted HR (95% CI) Cases Adjusted HR (95% CI)
SHBG (nmol/L)
<39.94 233,639 11 1.00 6 1.00 20 1.00 239 1.00
39.94 to <56.34 230,792 9 0.89 (0.36, 2.19) 13 1.88 (0.70, 5.04) 21 1.04 (0.55, 1.96) 210 0.91 (0.75, 1.10)
56.34 to <77.13 218,795 8 1.91 (0.35, 2.39) 9 1.28 (0.44, 3.74) 8 0.36 (0.15, 0.88) 219 1.01 (0.83, 1.23)
≥77.13 178,196 8 1.21 (0.44, 3.31) 14 2.03 (0.72, 5.75) 16 0.97 (0.46, 2.01) 171 0.97 (0.78, 1.21)
Missing 7 Ptrend=0.76 9 Ptrend=0.33 12 Ptrend=0.40 137 Ptrend=0.94
Testosterone (nmol/L)
<0.54 256,948 12 1.00 19 1.00 19 1.00 295 1.00
0.54 to <0.91 245,946 5 0.44 (0.15, 1.23) 16 0.89 (0.45, 1.75) 19 1.17 (0.61, 2.23) 211 0.78 (0.65, 0.93)
0.91 to <1.29 230,301 7 0.66 (0.26, 1.67) 5 0.33 (0.12, 0.88) 18 1.22 (0.63, 2.36) 206 0.83 (0.69, 0.99)
≥1.29 212,509 15 1.50 (0.70, 3.24) 9 0.66 (0.30, 1.47) 15 1.14 (0.57, 2.27) 191 0.83 (0.69, 1.00)
Missing 4 Ptrend=0.23 2 Ptrend=0.09 6 Ptrend=0.67 73 Ptrend=0.05
Free testosterone (nmol/L)
<0.006 219,576 9 1.00 18 1.00 17 1.00 260 1.00
0.006 to <0.01 215,286 5 0.57 (0.19, 1.69) 10 0.65 (0.29, 1.41) 16 1.08 (0.54, 2.17) 201 0.81 (0.68, 0.98)
0.01 to <0.02 213,233 10 1.12 (0.45, 2.77) 10 0.70 (0.32, 1.53) 16 1.11 (0.55, 2.24) 183 0.76 (0.63, 0.92)
≥0.02 209,615 12 1.30 (0.53, 3.20) 4 0.32 (0.11, 0.98) 15 1.12 (0.54, 2.31) 191 0.80 (0.66, 0.97)
Missing 7 Ptrend=0.35 9 Ptrend=0.05 13 Ptrend=0.75 141 Ptrend=0.01
Estradiol (pmol/L)
<175.0 853,825 34 1.00 45 1.00 67 1.00 838 1.00
≥175.0 33,918 1 0.94 (0.13, 6.94) 0 - 0 - 20 0.85 (0.54, 1.33)
Missing 8 6 10 118

Adjusted for age at baseline, deprivation, smoking status, BMI, alcohol consumption (except esophageal adenocarcinoma), diabetes, aspirin use and statin use (colorectal cancer only).